Physician profile
James E Fox
NPI 1952393688
$2,875.18
in general payments reported to CMS, 2019-2025
26 companies · $226 in 2025
The $226 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $957 · 2020: $472 · 2021: $424 · 2022: $331 · 2023: $400 · 2024: $65.32 · 2025: $226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $691.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $691.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $950.06 | 2019-2025 | Xtampza |
| Nevro Corp. | $459.96 | 2019-2023 | Senza |
| Daiichi Sankyo INC. | $305.56 | 2019 | |
| Pfizer INC. | $152.43 | 2019-2021 | |
| Scilex Pharmaceuticals INC. | $147.98 | 2019-2022 | |
| Redhill Biopharma INC. | $141.45 | 2020-2021 | |
| Almatica Pharma LLC | $120.93 | 2021-2023 | Gralise |
| Amgen INC. | $115.76 | 2019 | |
| Tonix Medicines, INC. | $84.05 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $78.41 | 2019-2023 | Relistor |
| Boston Scientific Corporation | $59.27 | 2023 | Wavewriter Alpha Prime 16 |
| Globus Medical, INC. | $29.10 | 2025 | Senza |
| Amneal Pharmaceuticals LLC | $25.12 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $23.12 | 2023 | Dysport |
| Vertex Pharmaceuticals Incorporated | $21.19 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $19.42 | 2022 | |
| Grt US Holding, INC. | $17.90 | 2021 | |
| Avanos Medical | $14.75 | 2019 | |
| Ibsa Pharma INC. | $14.65 | 2024 | Licart, Tirosint |
| Lilly USA, LLC | $14.43 | 2025 | Zepbound |
| Abbott Laboratories | $13.94 | 2022 | |
| Fidia Pharma USA INC. | $13.69 | 2022 | |
| Arbor Pharmaceuticals, INC. | $13.35 | 2019 | |
| Shionogi INC | $13.17 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.08 | 2022 | |
| Pacira Therapeutics, INC. | $12.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Fox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.